Xeris Biopharma Q4 2022 Earnings Report $3.20 -0.02 (-0.62%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Xeris Biopharma EPS ResultsActual EPS-$0.10Consensus EPS -$0.16Beat/MissBeat by +$0.06One Year Ago EPSN/AXeris Biopharma Revenue ResultsActual Revenue$33.14 millionExpected Revenue$31.04 millionBeat/MissBeat by +$2.10 millionYoY Revenue GrowthN/AXeris Biopharma Announcement DetailsQuarterQ4 2022Date3/8/2023TimeN/AConference Call ResourcesPress ReleaseXERS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Xeris Biopharma Earnings HeadlinesXeris Expects to Exceed Full-Year 2024 Financial GuidanceJanuary 10, 2025 | finance.yahoo.comXeris to Participate in Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | businesswire.comFree Stock Ticker Inside: This Indicator Caught Nvidia’s RalliesI’m not one to make super bold statements… But today, I’m making an exception. Because I’m 100% convinced this is the best indicator I’ve used for trading Nvidia… Don’t believe me? Just take a look at the last two rallies: This powerful indicator caught both moves almost perfectly.January 21, 2025 | ProsperityPub (Ad)Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before LongNovember 18, 2024 | finance.yahoo.comXeris Biopharma downgraded to Neutral from Overweight at Piper SandlerNovember 13, 2024 | markets.businessinsider.comXeris Biopharma price target raised to $6.60 from $6 at H.C. WainwrightNovember 13, 2024 | markets.businessinsider.comSee More Xeris Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xeris Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xeris Biopharma and other key companies, straight to your email. Email Address About Xeris BiopharmaXeris Biopharma (NASDAQ:XERS), a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.View Xeris Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025)Abbott Laboratories (1/22/2025)Johnson & Johnson (1/22/2025)Procter & Gamble (1/22/2025)Travelers Companies (1/22/2025)Progressive (1/22/2025)GE Vernova (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
